Srinivas Chava
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Srinivas Chava has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Isis Trujillo-Gonzalez
Nutrition Research Institute, University of North Carolina at Chapel Hill, Kannapolis, NC, USA; Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1 shared publication - Karuna Rasineni
Research Service Veterans Affairs Nebraska‐Western Iowa Health Care System Omaha Nebraska USA
1 shared publication - Kurt W. Fisher
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
1 shared publication - Kusum K. Kharbanda
Research Service Veterans Affairs Nebraska‐Western Iowa Health Care System Omaha Nebraska USA
1 shared publication - Madan Kumar Arumugam
Cancer Biology lab, Centre for Molecular and Nanomedical Sciences, Sathyabama Institute of Science and Technology, Chennai 600119, Tamil Nadu, India
1 shared publication - Natalia A. Osna
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA
1 shared publication
Latest Publications
- Open Access
- 11 June 2026
- Published by Portland Press Ltd. in Clinical Science
- Vol. 140 (7) , 1535-1549
Deletion of phosphatidylethanolamine methyltransferase promotes the spontaneous development of hepatic steatosis, inflammation and fibrosis in young mice
Phosphatidylethanolamine N-methyltransferase (PEMT) catalyzes the transfer of methyl groups to phosphatidylethanolamine (PE) to generate phosphatidylcholine (PC). PC produced de novo through this pathway is preferentially used for very‑low‑density lipoprotein assembly and is essential for its normal hepatic secretion as well as for bile acid detoxification. While human PEMT loss-of-function polymorphisms are linked to increased metabolic dysfunction-associated steatotic liver disease (MASLD) risk, the enzyme's role as a primary driver of progressive liver disease remains underexplored. We utilized PEMT knockout (PEMT KO) mice on a standard chow diet to model this deficiency. Histopathological analysis showed that while 2-month-old PEMT KO mice were protected, 6-month-old KOs of both sexes spontaneously developed extensive micro- and macrovesicular steatosis, parenchymal inflammation, and granulomatous inclusions. This severe, age-dependent pathology was confirmed by elevated hepatic triglyceride levels, bile acids, impaired methylation potential, and a cascade of secondary injuries, including increased oxidative stress, impaired proteasomal function, and the induction of cellular senescence markers. This bile acid toxicity and oxidative stress activated the central innate immune sensor, the NLRP3 inflammasome, driving pronounced macrophage infiltration and chronic inflammation. Picrosirius red staining and protein analysis confirmed the progression to severe pericellular fibrosis. Our study establishes that PEMT deficiency is sufficient to initiate and drive the complete progression from steatosis to advanced liver fibrosis, identifying PEMT as a critical metabolic checkpoint and a potent therapeutic target for mitigating progressive liver disease.
- 11 June 2026
- Published by Portland Press Ltd. in Clinical Science
- Vol. 140 (7) , 1535-1549
Open AccessDeletion of phosphatidylethanolamine methyltransferase promotes the spontaneous development of hepatic steatosis, inflammation and fibrosis in young mice
Phosphatidylethanolamine N-methyltransferase (PEMT) catalyzes the transfer of methyl groups to phosphatidylethanolamine (PE) to generate phosphatidylcholine (PC). PC produced de novo through this pathway is preferentially used for very‑low‑density lipoprotein assembly and is essential for its normal hepatic secretion as well as for bile acid detoxification. While human PEMT loss-of-function polymorphisms are linked to increased metabolic dysfunction-associated steatotic liver disease (MASLD) risk, the enzyme's role as a primary driver of progressive liver disease remains underexplored. We utilized PEMT knockout (PEMT KO) mice on a standard chow diet to model this deficiency. Histopathological analysis showed that while 2-month-old PEMT KO mice were protected, 6-month-old KOs of both sexes spontaneously developed extensive micro- and macrovesicular steatosis, parenchymal inflammation, and granulomatous inclusions. This severe, age-dependent pathology was confirmed by elevated hepatic triglyceride levels, bile acids, impaired methylation potential, and a cascade of secondary injuries, including increased oxidative stress, impaired proteasomal function, and the induction of cellular senescence markers. This bile acid toxicity and oxidative stress activated the central innate immune sensor, the NLRP3 inflammasome, driving pronounced macrophage infiltration and chronic inflammation. Picrosirius red staining and protein analysis confirmed the progression to severe pericellular fibrosis. Our study establishes that PEMT deficiency is sufficient to initiate and drive the complete progression from steatosis to advanced liver fibrosis, identifying PEMT as a critical metabolic checkpoint and a potent therapeutic target for mitigating progressive liver disease.